losartan has been researched along with Atypical Ductal Hyperplasia in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coulson, R | 1 |
| Liew, SH | 1 |
| Connelly, AA | 1 |
| Yee, NS | 1 |
| Deb, S | 1 |
| Kumar, B | 1 |
| Vargas, AC | 1 |
| O'Toole, SA | 1 |
| Parslow, AC | 1 |
| Poh, A | 1 |
| Putoczki, T | 1 |
| Morrow, RJ | 1 |
| Alorro, M | 1 |
| Lazarus, KA | 1 |
| Yeap, EFW | 1 |
| Walton, KL | 1 |
| Harrison, CA | 1 |
| Hannan, NJ | 1 |
| George, AJ | 1 |
| Clyne, CD | 1 |
| Ernst, M | 1 |
| Allen, AM | 1 |
| Chand, AL | 1 |
1 other study available for losartan and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiotensin II Type 1 Receptor Blockers; Animals; Biopsy; Breast N | 2017 |